Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-15
2008-07-15
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
10279733
ABSTRACT:
The invention provided compositions and methods to initiate site-specific thrombosis in tumor vasculature. The present invention also provides methods for using the disclosed compositions and methods to treat tumors.
REFERENCES:
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4938949 (1990-07-01), Borch et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 5017556 (1991-05-01), O'Brien et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5183756 (1993-02-01), Schlom
patent: 5223427 (1993-06-01), Edgington et al.
patent: 5242813 (1993-09-01), Pastan et al.
patent: 5288641 (1994-02-01), Roizman
patent: 5346991 (1994-09-01), Roy et al.
patent: 5374617 (1994-12-01), Morrissey et al.
patent: 5437864 (1995-08-01), Edgington et al.
patent: 5504064 (1996-04-01), Morrissey et al.
patent: 5504067 (1996-04-01), Morrissey et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 5589363 (1996-12-01), Roy et al.
patent: 5795877 (1998-08-01), Jackson et al.
patent: 5804602 (1998-09-01), Slusher et al.
patent: 5863536 (1999-01-01), Jackson et al.
patent: 5880112 (1999-03-01), Jackson et al.
patent: 5902817 (1999-05-01), Jackson et al.
patent: 5968915 (1999-10-01), Jackson et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6156321 (2000-12-01), Thorpe et al.
patent: WO-93/17715 (1993-09-01), None
patent: WO-94/05328 (1994-03-01), None
patent: WO-94/07515 (1994-04-01), None
patent: WO-94/28017 (1994-12-01), None
patent: WO-96/01653 (1996-01-01), None
patent: WO-97/48409 (1997-12-01), None
Akiyama, S.K., Human Cell, 1996, vol. 9: pp. 181-186.
Abraham, Judith A., et al., “Nucleotide Sequence of a Bovine Clone Encoding the Angiogenic Protein, Basic Fibroblast Growth Factor”,Science, 233, (1986),545-548.
Abrams, Paul G., et al., “Monoclonal Antibody Therapy of Solid Tumors”,In: Monoclonal Antibody Therapy of Human Cancer, Foon, Kenneth A., and Alton C. Morgan, Jr., eds. Martinus Nijhoff Publishing: Boston,(1985),103-120.
Bach, Ronald , et al., “Factor VII Binding to Tissue Factor in Reconstituted Phospholipid Vesicles: Induction of Cooperativity by Phosphatidylserine”,Biochemistry, 25, (1986),4007-4020.
Bauer, Therese , et al., “Bispecific Antibodies and Targeted Cellular Cytotoxicity: Therapeutic Hopes Confirmed”,Vox Sanguinis, 61, (1991),156-157.
Baxter, Laurence T., et al., “Transport of Fluid and Macromolecules in Tumors III. Role in Binding and Metabolism”,Microvascular Research, 41, (1991),5-23.
Bevilacqua, Michael P., et al., “Identification of an Inducible Endothelial-Leukocyte Adhesion Molecule”,Proceedings of the National Academy of Sciences, 84, (1987),9238-9242.
Bhagwat, Shripad S., et al., “Synthesis and Structure of the Platelet Aggregation Factor Thromboxane A2”,Nature, 315, (1985),511-513.
Bicknell, R. , et al., “Anticancer Strategies Involving the Vasculature: Vascular Targeting and the Inhibition of Angiogenesis”,Cancer Biology, 3, (1992),399-407.
Birembaut, P. , et al., “Usefulness of Basement Membrane Markers in Tumoural Pathology”,Journal of Pathology, 145, (1985),283-296.
Bjorndahl, Jay M., et al., “Human T Cell Activation: Differential Response to Anti-CD28 as Compared to Anti-CD3 Monoclonal Antibodies”,European Journal of Immunology, 19, (1989),881-887.
Borden, Ernest C., et al., “Lymphokines and Cytokines as Cancer Treatment: Immunotherapy Realized”,Cancer, 65, (1990),800-814.
Brennan, Maureen, et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments”,Science, 229, (1985),81-83.
Brinkmann, Ulrich , et al., “B3(Fv)-PE38KDEL, a Single-Chain Immunotoxin that Causes Complete Regression of a Human Carcinoma in Mice”,Proceedings of the National Academy of Sciences, 88, (1991),8616-8620.
Broze, Jr., George J., “The Role of Tissue Factor Pathway Inhibitor in a Revised Coagulation Cascade”,Seminars in Hematology, 29, (1992),159-169.
Burchell, Joy , et al., “Complexity of Expression of Antigenic Determinants, Recognized by Monoclonal Antibodies HMFG-1 and HMFG-2, in Normal and Malignant Human Mammary Epithelial Cells”,Journal of Immunology, 131, (1983),508-513.
Burrows, Francis J., et al., “A Murine Model for Antibody-Directed Targeting of Vascular Endothelial Cells in Solid Tumors”,Cancer Research, 52, (1992),5954-5962.
Burrows, Francis J., et al., “Eradication of Large Solid Tumors in Mice with an Immuotoxin Directed Against Tumor Vasculature”,Proceedings of the National Acacemy of Sciences, 90, (1993),8996-9000.
Burrows, Francis J., et al., “Influence of Tumor-Derived Interleukin 1 on Melanoma-Endothelial Cell Interactions in Vitro”,Cancer Research, 51, (1991),4768-4775.
Burtin, P. , et al., “Alterations of the Basement Membrane and Connective Tissue Antigens in Human Metastatic Lymph Nodes”,International Journal of Cancer, 31, (1983),719-726.
Byers, V. S., et al., “Therapeutic Strategies with Monoclonal Antibodies and Immunoconjugates”,Immunology, 65, (1988),329-335.
Campbell, “Selection of Animals and Cell Lines 3.4”,In: Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology, 13, Burdon, R.H. and P.H. van Knippenberg, eds. Elsevier: Amsterdam,(1984),75-83.
Carmeliet, Peter , et al., “Role of Tissue Factor in Embryonic Blood Vessel Development”,Nature, 383, (1996),73-75.
Carter, Ruth E., et al., “Prostate-Specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase”,Proceedings of the National Academy of Sciences, 93, (1996),749-753.
Chang, Sam S., et al., “Five Different Anti-Prostate-Specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature”,Cancer Research, 59, (1999),3192-3198.
Chen, Tai-Ying , et al., “Induction of Macrophage-Mediated Tumor Cytotoxicity by a Hamster Monoclonal Antibody with Specificity for Lipopolysaccharide Receptor”,Journal of Immunology, 145, (1990),8-12.
Further Differences in Lymphokine Synthesis Between Th1 and Th2 Clones Revealed by RNA Hybridization, Functionally Monospecific Bioassays, and Monoclonal Antibodies,Journal of Experimental Medicine, 166, (1987),1229-1244.
Clark, Gary M., et al., “Follow-up Study of HER-2
eu Amplification in Primary Breast Cancer”,Cancer Research, 51, (1991),944-948.
Clark, Adrian , et al., “Synthesis of Epidermal Growth Factor (EGF) Receptor In Vitro Using SP6 RNA Polymerase-Transcribed Template mRNA”,Biochimica et Biophysica Acta, 867, (1986),244-251.
Clark, Mike , et al., “The Potential of Hybrid Antibodies Secreted by Hybrid-Hybridomas in Tumour Therapy”,International Journal of Cancer: Supp. 2, (1988),15-17.
Colcher, David , et al., “Complementation of Intracavitary and Intravenous Administration of a Monoclonal Antibody (B72.3) in Patients with Carcinoma”,Cancer Research, 47, (1987),4218-4224.
Colcher, David , et al., “Quantitive Analyses of Selective Radiolabeled Monoclonal Antibody Localization in Metastatic Lesions of Colorectal Cancer Patients”,Cancer Research, 47, (1987),1185-1189.
Collins, Tucker , et al., “Immune Interferon Activates Multiple Class II Major Histocompatibility Complex Genes and the Associated Invariant Chain Gene in Human Endothelial Cells and Dermal Fibroblasts”,Proceedings of the National Academy of Sciences, 81, (1984),4917-4921.
Cotran, Ramzi S., et al., “Induction and Detection of a Human Endothelial Activation Antigen In Vivo”,Journal of Experimental Medicine, 164, (1986),661-666.
Daar, A. S., et al., “The Detailed Distribution of MHC Class II Antigens in N
Edgington Thomas S.
Liu Cheng
Fetterolf Brandon J
Fitting Thomas
McCarthy Michael J.
The Scripps Research Institute
Wang Hugh
LandOfFree
Targeted thrombosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted thrombosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted thrombosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3953987